Entrada Therapeutics Inc (TRDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $199.28M
Last updated: Nov 17, 2026 at 11:05 AM ET
Entrada Therapeutics Inc (TRDA) Earnings: Report Dates and Results
Entrada Therapeutics (TRDA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Entrada Therapeutics reported EPS of -$0.94, above the -$0.98 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TRDA has an expected report date of Feb 24, 2027.
Earnings History
Of the 21 quarters below that had an estimate, TRDA beat 13 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $905000, down 43.8% from $1.61M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.94 | -$0.98 | -$1.22 - -$0.62 | +4.08% | Beat | N/A | 6 | 1 up, 1 down | Nov 5, 2026 | $905000 |
| Jun 30, 2026 | -$1.01 | -$1.16 | -$1.34 - -$0.68 | +12.93% | Beat | N/A | 7 | 3 up, 3 down | Aug 5, 2026 | $898000 |
| Mar 31, 2026 | -$0.95 | -$1.02 | -$1.16 - -$0.67 | +6.86% | Beat | N/A | 7 | 2 up, 2 down | May 7, 2026 | $875000 |
| Dec 31, 2025 | -$0.94 | -$1.32 | -$2.10 - -$0.60 | +28.79% | Beat | -3233.3% | 6 | 3 up, 1 down | Feb 26, 2026 | $1.30M |
| Sep 30, 2025 | -$1.06 | -$0.96 | -$1.13 - -$0.74 | -10.42% | Miss | N/A | 4 | 0 up, 2 down | Nov 6, 2025 | $1.61M |
| Jun 30, 2025 | -$1.04 | -$0.86 | -$0.98 - -$0.72 | -20.93% | Miss | -167.1% | 3 | 2 up, 1 down | Aug 6, 2025 | $1.95M |
| Mar 31, 2025 | -$0.42 | -$0.77 | -$0.92 - -$0.70 | +45.45% | Beat | -161.8% | 4 | 0 up, 0 down | May 8, 2025 | $20.56M |
| Dec 31, 2024 | $0.03 | -$0.67 | -$0.69 - -$0.62 | +104.48% | Beat | N/A | 5 | 2 up, 1 down | Feb 27, 2025 | $37.40M |
| Sep 30, 2024 | -$0.35 | -$0.62 | -$1.14 - -$0.47 | +43.55% | Beat | -134.3% | 5 | 0 up, 0 down | Nov 5, 2024 | $19.57M |
| Jun 30, 2024 | $1.55 | $0.33 | -$0.41 - $0.77 | +369.70% | Beat | N/A | 4 | 0 up, 0 down | Aug 13, 2024 | $94.69M |
| Mar 31, 2024 | $0.68 | -$0.47 | -$1.10 - -$0.01 | +244.68% | Beat | N/A | 5 | 0 up, 0 down | May 7, 2024 | $59.12M |
| Dec 31, 2023 | -$0.29 | -$0.17 | -$0.53 - $0.21 | -70.59% | Miss | N/A | 5 | 0 up, 0 down | Mar 13, 2024 | $41.85M |
| Sep 30, 2023 | $1.02 | -$0.63 | -$1.04 - -$0.39 | +261.90% | Beat | N/A | 4 | 0 up, 0 down | Nov 7, 2023 | $43.73M |
| Jun 30, 2023 | -$0.78 | -$0.60 | -$0.96 - -$0.23 | -30.00% | Miss | N/A | 4 | 0 up, 0 down | Aug 8, 2023 | $18.17M |
| Mar 31, 2023 | -$0.21 | -$0.84 | -$0.84 - $5.97 | +75.00% | Beat | N/A | 4 | 1 up, 0 down | May 10, 2023 | $25.26M |
| Dec 31, 2022 | -$0.79 | -$0.83 | -$0.84 - -$0.82 | +4.82% | Beat | N/A | 3 | 0 up, 0 down | Mar 6, 2023 | N/A |
| Sep 30, 2022 | -$0.80 | -$0.77 | -$0.77 - -$0.75 | -3.90% | Miss | N/A | 2 | 0 up, 0 down | Nov 7, 2022 | N/A |
| Jun 30, 2022 | -$0.74 | -$0.73 | N/A | -1.37% | Miss | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$0.69 | -$0.65 | -$0.66 - -$0.65 | -6.15% | Miss | N/A | 2 | 0 up, 0 down | May 12, 2022 | N/A |
| Dec 31, 2021 | -$0.89 | -$1.28 | -$1.85 - -$0.72 | +30.47% | Beat | N/A | 2 | 0 up, 0 down | Mar 15, 2022 | N/A |
| Sep 30, 2021 | -$9.78 | -$0.91 | -$0.91 - -$0.83 | -974.73% | Miss | N/A | 2 | 0 up, 0 down | Nov 1, 2021 | N/A |
| Jun 30, 2021 | -$0.45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 1, 2021 | N/A |
| Mar 31, 2021 | -$7.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | N/A |
| Dec 31, 2020 | -$7.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Mar 31, 2020 | -$5.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | -$5.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.46, after $1.91 the year before. It was -$5.18 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.46 | -281.2% |
| Dec 31, 2024 | $1.91 | N/A |
| Dec 31, 2023 | -$0.26 | N/A |
| Dec 31, 2022 | -$3.02 | N/A |
| Dec 31, 2021 | -$18.20 | N/A |
| Dec 31, 2020 | -$12.26 | N/A |
| Dec 31, 2019 | -$5.18 | N/A |
Frequently Asked Questions About TRDA
When is Entrada Therapeutics's next earnings date?
Entrada Therapeutics's next earnings report is expected for Feb 24, 2027.
Did TRDA beat earnings estimates last quarter?
Yes. Entrada Therapeutics reported EPS of -$0.94 for the quarter ended Sep 30, 2026, above the -$0.98 estimate, a 4.08% surprise.
What EPS do analysts expect from TRDA next quarter?
The consensus EPS estimate for Entrada Therapeutics for the quarter ending Dec 31, 2026 is -$1.13 from 9 analysts, with estimates from -$1.85 to -$0.71.
How often does TRDA beat earnings estimates?
Entrada Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +21.41%.
TRDA pages: Overview, Earnings, Forecast, Financials, Competitors